A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Enalapril in Healthy Volunteers
NCT01115946 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2010-05-27
Summary
This study is to assess the effect of ASP1585 on pharmacokinetics of enalapril in 2x2 crossover method.
Conditions
- Healthy
- Pharmacokinetics of Enalapril
Interventions
- DRUG
-
ASP1585
oral
- DRUG
-
enalapril
oral
Sponsors & Collaborators
-
Astellas Pharma Inc
lead INDUSTRY
Principal Investigators
-
Use Central Contact · Astellas Pharma Inc
Study Design
- Allocation
- RANDOMIZED
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 20 Years
- Max Age
- 44 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-03-31
- Primary Completion
- 2010-04-30
- Completion
- 2010-04-30
Countries
- Japan
Study Locations
More Related Trials
-
Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan
NCT01424319 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus
NCT00419835 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
NCT02358096 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients
NCT01351636 ·Status: COMPLETED ·Phase: PHASE4
-
Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes
NCT00461136 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
NCT01356849 ·Status: COMPLETED ·Phase: PHASE2
-
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824 ·Status: RECRUITING ·Phase: PHASE3
-
The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution
NCT00741156 ·Status: COMPLETED ·Phase: PHASE3
-
The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables
NCT01195805 ·Status: COMPLETED ·Phase: NA
-
Eplerenone, ACE Inhibition and Albuminuria
NCT00315016 ·Status: COMPLETED ·Phase: PHASE2
-
Influence of Aliskiren on Proteinuria
NCT01219413 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients
NCT01503671 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effect of Amiloride and Spironolactone in Healthy Persons
NCT00857909 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Atorvastatin on Renal Function in Healthy Subjects During Normal and High Sodium Intake
NCT00678184 ·Status: COMPLETED ·Phase: PHASE4
-
Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System
NCT00528385 ·Status: COMPLETED ·Phase: NA
-
High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy
NCT00212901 ·Status: COMPLETED ·Phase: NA
-
Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network
NCT00113087 ·Status: COMPLETED ·Phase: PHASE3
-
Azilsartan in Patients With Diabetic Kidney Disease and Hypertension
NCT05753696 ·Status: UNKNOWN ·Phase: NA
-
Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria
NCT01500590 ·Status: UNKNOWN ·Phase: PHASE4
-
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
NCT01036659 ·Status: UNKNOWN ·Phase: PHASE2
-
A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers
NCT01314898 ·Status: COMPLETED ·Phase: PHASE1
-
Atorvastatin and Sympathetic Activity in Chronic Kidney Disease
NCT01257009 ·Status: COMPLETED ·Phase: PHASE4
-
Study of CS-3150 in Patients With Primary Aldosteronism
NCT02885662 ·Status: COMPLETED ·Phase: NA
-
Hypertension in Hemodialysis Patients (Aim 3)
NCT00582114 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986 ·Status: RECRUITING ·Phase: PHASE2